New combo aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07245797
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests whether adding the drug inavolisib to standard targeted therapy and chemotherapy can eliminate more breast cancer before surgery in people with a specific genetic mutation (PIK3CA) and HER2-positive early breast cancer. About 164 participants will receive either the standard treatment or the standard plus inavolisib for 6 cycles, then have surgery to check if the cancer is gone. The goal is to see if the new combination improves the chance of having no cancer left at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.